scholarly journals PRESERFLO MicroShunt

2020 ◽  
pp. 91-103
Author(s):  
Nathan M. Kerr ◽  
Iqbal Ike K. Ahmed ◽  
Leonard Pinchuk ◽  
Omar Sadruddin ◽  
Paul F. Palmberg
Keyword(s):  
Clinical Trials ◽  
Intraocular Pressure ◽  
Foreign Body ◽  
Gold Standard ◽  
Aqueous Humour ◽  
Pressure Reduction ◽  
Scleral Flap ◽  
Current Gold Standard ◽  
Intraocular Pressure Reduction ◽  
Poiseuille Equation

Abstract The PRESERFLO® MicroShunt (Santen Pharmaceutical Co. Ltd., Osaka, Japan), formerly called the InnFocus MicroShunt®, is a trans-scleral device that shunts aqueous humour from the anterior chamber to a filtering bleb under the conjunctiva and Tenon’s capsule. Manufactured from an inert biocompatible material called poly(styrene-block-isobutylene-block-styrene), or ‘SIBS’, the device elicits minimal foreign body reaction and inflammation; potentially reducing the risk of bleb-related fibrosis and failure. The MicroShunt is 8.5 mm long with a 70 μm lumen and is designed to minimize hypotony based on the Hagen–Poiseuille equation. Inserted via an ab-externo approach, the MicroShunt eliminates the need for creation of a scleral flap, sclerostomy, iridectomy, scleral flap suturing and postoperative suture lysis. Clinical trials show promising results with the MicroShunt achieving intraocular pressure reduction approaching that of trabeculectomy, the current gold standard for treating refractory glaucoma.

The Relationship between Intraocular Pressure Reduction and Rates of Progressive Visual Field Loss in Eyes with Optic Disc Hemorrhage

Ophthalmology ◽  
2010 ◽  
Vol 117 (11) ◽  
pp. 2061-2066 ◽  
Author(s):  
Felipe A. Medeiros ◽  
Luciana M. Alencar ◽  
Pamela A. Sample ◽  
Linda M. Zangwill ◽  
Remo Susanna Jr. ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Visual Field ◽  
Optic Disc ◽  
Visual Field Loss ◽  
Pressure Reduction ◽  
Disc Hemorrhage ◽  
Intraocular Pressure Reduction ◽  
The Relationship

Intraocular Pressure Reduction in the Treatment of Normal-Tension Glaucoma

2020 ◽  
pp. 67-72
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Clinical Trial ◽  
Intraocular Pressure ◽  
Visual Field ◽  
Natural History ◽  
Visual Loss ◽  
Normal Tension Glaucoma ◽  
Pressure Reduction ◽  
Glaucomatous Damage ◽  
Intraocular Pressure Reduction ◽  
History Of

The Collaborative Normal-Tension Glaucoma Study (CNTGS) was a randomized clinical trial to determine the effectiveness of a 30% reduction in intraocular pressure (IOP) (using either medical therapy or filtration surgery) on visual field (VF) progression in eyes with normal-tension glaucoma. The study found that reducing the IOP of patients with normal-tension glaucoma by 30% is beneficial to prevent progression of glaucomatous damage if the visual effects of cataracts are excluded from consideration. However, because not all untreated patients progressed, the natural history of normal-tension glaucoma must be considered before embarking on IOP reduction with therapy that may exacerbate cataract formation, unless normal-tension glaucoma threatens serious visual loss.

Sign in / Sign up

Export Citation Format

Share Document